Ligand to Report Third Quarter Results on October 30th
SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2013 financial results on Wednesday, October 30, 2013. Ligand’s President and CEO, John Higgins, Executive Vice President and COO, Matt Foehr and Vice President of Finance and CFO, John Sharp will host the conference call.
Third Quarter Earnings Call
|
What: |
Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates. |
||||
|
When: |
Wednesday, October 30, 2013 |
||||
|
Time: |
6:00 a.m. Pacific time (9:00 a.m. Eastern time) |
||||
|
Webcast: |
Conference call and replay accessible at www.ligand.com |
||||
|
Conference Call: |
(877) 407-4019, passcode: Ligand |
||||
| (201) 689-8337 outside the U.S. | |||||
|
Replay: |
(877) 660-6853, passcode: 420734 |
||||
| (201) 612-7415 outside the U.S. | |||||
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.
Follow Ligand on Twitter @Ligand_LGND.
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
(858)
550-7500
or
LHA
Don Markley
(310) 691-7100
[email protected]
Source: Ligand Pharmaceuticals Incorporated
Released October 9, 2013